CoChat

DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide

Open access
Wysham, C., Bergenstal, R., Malloy, J., Yan, P., Walsh, B., Malone, J., Taylor, K. · 2011 · Diabetic Medicine
Cited by 118

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 28, 705–714 (2011) Aims In the initial 26‐week, double‐blind, double‐dummy assessment period of the DURATION‐2 trial in patients with Type 2 diabetes on metformin, the once‐weekly glucagon‐like peptide 1 (GLP‐1) receptor agonist exenatide once‐weekly resulted in greater HbA 1c improvement and weight reduction compared with maximum approved daily doses of sitagliptin or pioglitazone. This subsequent, 26‐week, open‐label, uncontrolled assessment period evaluated the safety and efficacy of (i) continued exenatide once‐weekly treatment and (ii) switching from sitagliptin or pioglitazone to exenatide once‐weekly. Methods Randomised oral medications were discontinued and all patients received exenatide once‐weekly. Of the 364 patients [original baseline HbA 1c 8.5 ± 1.1% (70 mmol/mol), fasting plasma glucose 9.0 ± 2.5 mmol/l, weight 88 ± 20 kg) who continued into the open‐label period, 319 patients (88%) completed 52 weeks. Results Evaluable patients who received only exenatide once‐weekly demonstrated significant 52‐week improvements (least square mean ± se) in HbA 1c (−1.6 ± 0.1%), fasting plasma glucose (−1.8 ± 0.3 mmol/l) and weight (−1.8 ± 0.5 kg). Evaluable patients who switched from sitagliptin to exenatide once‐weekly demonstrated significant incremental improvements in HbA 1c (−0.3 ± 0.1%), fasting plasma glucose (−0.7 ± 0.2 mmol/l) and weight (−1.1 ± 0.3 kg). Patients who switched from pioglitazone to exenatide once‐weekly maintained HbA 1c and fasting plasma glucose improvements (week 52: −1.6 ± 0.1%, −1.7 ± 0.3 mmol/l), with significant weight reduction (−3.0 ± 0.3 kg). Exenatide once‐weekly was generally well tolerated and adverse events were predominantly mild or moderate in intensity. Nausea was the most frequent adverse event in this assessment period (intent‐to‐treat: exenatide once‐weekly‐only 5%; sitagliptin → exenatide once‐weekly 11%; pioglitazone → exenatide once‐weekly 10%). No major hypoglycaemia was observed. Conclusions Patients who switched to once‐weekly exenatide from daily sitagliptin or pioglitazone had improved or sustained glycaemic control, with weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2011.03301.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 10

  1. 10.4158/EP.15.6.540 · DOI · Paper page
  2. 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
  3. 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  4. 10.2337/dc09-1914 · DOI · Paper page
  5. Goke R, 1993, Exendin‐4 is a high potency agonist and truncated exendin‐(9‐39)‐amide an antagonist at the glucagon‐like peptide 1‐(7‐36)‐amide receptor of insulin‐secreting β‐cells, J Biol Chem, 268, 19650, 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
  6. 10.1053/meta.2001.22519 · DOI · Paper page
  7. 10.2337/diacare.28.7.1547 · DOI · Paper page
  8. 10.1001/archinternmed.2009.471 · DOI
  9. 10.1161/CIRCULATIONAHA.109.884866 · DOI · Paper page
  10. 10.2337/dc09-2376 · doi:10.2337/dc09-2376

Cited by

See all 118

Metadata

Authors
Wysham, C., Bergenstal, R., Malloy, J., Yan, P., Walsh, B., Malone, J., & Taylor, K.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2011-05-16
Volume
28
Issue
6
Pages
705-714
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1518543897
Cited by
118
References
4
FWCI
16.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide. https://app.cochat.ai/papers/10.1111/j.1464-5491.2011.03301.x
The paper
Wysham, C., Bergenstal, R., Malloy, J., Yan, P., Walsh, B., Malone, J., & Taylor, K. (2011). DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2011.03301.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.